Also known as Verzenio.
FDA grants full approval to the all‑oral imlunestrant + abemaciclib combination for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after prior endocrine therapy.
Inluriyo™ improves survival in ER+, HER2- breast cancer, both alone and with abemaciclib, extending time to chemotherapy and showing durable benefits across patient groups.
